SEARCH

SEARCH BY CITATION

References

  • 1
    Trey C, Lipworth L, Chalmers TC, et al. Fulminant hepatic failure. Presumable contribution to halothane. N Engl J Med 1968;279: 798 801.
  • 2
    Davidson CS, McDermott WV, Trey C. Sustaining life during fulminant hepatic failure. Ann Intern Med 1969; 71: 415 18.
  • 3
    Plevris JN, Schina M, Hayes PC. Review article: the management of acute liver failure. Aliment Pharmacol Ther 1998; 12: 405 18.
  • 4
    Ejlersen E, Larsen FS, Pott F, Gyrtrup HJ, Kirkegaard P, Secher NH. Hepatectomy corrects cerebral hyperperfusion in fulminant hepatic failure. Transplant Proc 1994; 26: 1794 5.
  • 5
    Kerr DN, Elliott RW, Swinney J. Regular haemodialysis in the treatment of chronic renal failure. Proc R Soc Med 1966; 59: 667 70.
  • 6
    Rees HA, Goldberg A, Cochrane AL, Williams MJ, Donald KW. Renal haemodialysis in porphyria. Lancet 1967; 1: 919 22.
  • 7
    Zysno E, Reichenmiller HE, Durr F. EEG studies in uraemic patients during extracorporeal haemodialysis or intermittent peritoneal dialysis. Electroencephalogr Clin Neurophysiol 1967; 23: 384384.
  • 8
    Zysno E, Reichenmiller HE, Durr F. [Longitudinal EEG study of uremic patients treated by extracorporeal hemodialysis and by intermittent peritoneal dialysis]. Rev Neurol (Paris) 1967; 117: 128 30.
  • 9
    Kiley JE, Pender JC, Welch CS, et al. Treatment of hepatic coma by hemodialysis. Trans Am Soc Artif Intern Organs 1957; 3: A86 8(Abstract).
  • 10
    Keynes WM. Haemodialysis in the treatment of liver failure. Lancet 1968; 2: 1236 8.
  • 11
    Oules R, Asaba H, Neuhauser M, et al. The removal of uremic small and middle molecules and free amino acids by carbon hemoperfusion. Trans Am Soc Artif Intern Organs 1977; 23: 583 90.
  • 12
    Opolon P, Lavallard MC, Crubille C, et al. [Encephalopathy in acute hepatic atrophy. Effect of the purification of middle molecules. Preliminary results]. Nouv Presse Med 1975; 4: 2987 91.
  • 13
    Colombi A & Tholen H. Haemodialysis in the treatment of lactic acidosis associated with acute hepatic and renal failure. Postgrad Med J 1971; 47: 628 31.
  • 14
    Opolon P, Lavallard MC, Crubille C, et al. [Effect of molecular filtration on encephalopathy during coma caused by acute hepatic atrophy: preliminary results]. Med Chir Dig 1975; 4(Suppl. 2): 37 41.
  • 15
    Denis J, Opolon P, Nusinovici V, Granger A, Darnis F. Treatment of encephalopathy during fulminant hepatic failure by haemodialysis with high permeability membrane. Gut 1978; 19: 787 93.
  • 16
    Gohl H, Konstantin P, Gullberg CA. Hemofiltration membranes. Contrib Nephrol 1982; 32: 20 30.
  • 17
    Stange J & Mitzner S. A carrier-mediated transport of toxins in a hybrid membrane. Safety barrier between a patients blood and a bioartificial liver. Int J Artif Organs 1996; 19: A677 91(Abstract).
  • 18
    Klammt S, Stange J, Mitzner S. Reduction of hospital treatment time for chronic liver failure by albumin dialysis (MARS). J Hepatol 1999; 30(Suppl. 1): 8686.
  • 19
    Mitzner S, Stange J, Klammt S. Albumin dialysis “MARS”. Clinical results in hepatorenal syndrome (HRS)—treatment. J Hepatol 1999; 30(Suppl. 1): A83A83(Abstract).
  • 20
    Clemmesen JO, Larsen FS, Ejlersen E, Schiodt FV, Ott P, Hansen BA. Haemodynamic changes after high-volume plasmapheresis in patients with chronic and acute liver failure. Eur J Gastroenterol Hepatol 1997; 9: 55 60.
  • 21
    Davenport A, Will EJ, Davison AM. Continuous vs. intermittent forms of haemofiltration and/or dialysis in the management of acute renal failure in patients with defective cerebral autoregulation at risk of cerebral oedema. Contrib Nephrol 1991; 93: 225 33.
  • 22
    Davenport A, Will EJ, Davison AM, et al. Changes in intracranial pressure during machine and continuous haemofiltration. Int J Artif Organs 1989; 12: 439 44.
  • 23
    Davenport A, Will EJ, Davison AM. The effect of lactate-buffered solutions on the acid–base status of patients with renal failure. Nephrol Dial Transplant 1989; 4: 800 4.
  • 24
    Davenport A, Will EJ, Davison AM. Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure. Nephron 1994; 66: 431 7.
  • 25
    Bellomo R & Ronco C. Circulation of the continuous artificial kidney: blood flow, pressures, clearances and the search for the best. Blood Purif 1997; 15: 354 65.
  • 26
    Ronco C & Bellomo R. Basic mechanisms and definitions for continuous renal replacement therapies. Int J Artif Organs 1996; 19: 95 9.
  • 27
    Bellomo R & Ronco C. Continuous versus intermittent renal replacement therapy in the intensive care unit. Kidney Int Suppl 1998; 66: S125 8.
  • 28
    Bellomo R, Baldwin I, Cole L, Ronco C. Preliminary experience with high-volume hemofiltration in human septic shock. Kidney Int Suppl 1998; 66: S182 5.
  • 29
    Yoshiba M, Inoue K, Sekiyama K, Koh I. Favorable effect of new artificial liver support on survival of patients with fulminant hepatic failure. Artif Organs 1996; 20: 1169 72.
  • 30
    Yatzidis H. A convenient hemoperfusion microapparatus over charcoal for the treatment of endogenous and exogenous intoxifications: its use as an effective kidney. Proc Eur Dial Transplant Assoc 1964; 1: 83 7.
  • 31
    Medd RK, Widdop B, Braithwaite RA, Rees AJ, Goulding R. Comparison of haemoperfusion and haemodialysis in the therapy of barbiturate intoxication in dogs. Arch Toxicol 1973; 31: 163 74.
  • 32
    Widdop B, Medd RK, Braithwaite RA, Rees AJ, Goulding R. Experimental drug intoxication: treatment with charcoal haemoperfusion. Arch Toxicol 1975; 34: 27 36.
  • 33
    Willson RA, Thompson RP, Winch J, Williams R. Rapid removal of paracetamol by haemoperfusion through coated charcoal. In vivo and in vitro studies in the pig. Lancet 1973; 1: 77 9.
  • 34
    Chang TM. Biotechnological and medical applications based on immobilization of hepatocytes, microorganisms, or enzyme systems by microencapsulation in artificial cells. Ann NY Acad Sci 1990; 613: 109 15.
  • 35
    Gazzard BG, Weston MJ, Murray Lyon IM, et al. Charcoal haemoperfusion in the treatment of fulminant hepatic failure. Lancet 1974; 1: 1301 7.
  • 36
    Weston MJ, Gazzard BG, Buxton BH, et al. Effects of haemoperfusion through charcoal or XAD-2 resin on an animal model of fulminant liver failure. Gut 1974; 15: 482 6.
  • 37
    Horak J, Horky J, Rabl M. Haemoperfusion through activated charcoal in dogs with fulminant liver failure. Digestion 1980; 20: 22 30.
  • 38
    Weston MJ, Langley PG, Rubin MH, Hanid MA, Mellon P, Williams R. Platelet function in fulminant hepatic failure and effect of charcoal haemoperfusion. Gut 1977; 18: 897 902.
  • 39
    Gelfrand MC & Winchester JF. Treatment of hepatic coma with hemoperfusion through polyacrylamide hydrogel-coated charcoal. Kidney Int 1976; 12: A239 43(Abstract).
  • 40
    Gimson AE, Braude S, Mellon PJ, Canalese J, Williams R. Earlier charcoal haemoperfusion in fulminant hepatic failure. Lancet 1982; 2: 681 3.
  • 41
    Gimson AE, Langley PG, Hughes RD, et al. Prostacyclin to prevent platelet activation during charcoal haemoperfusion in fulminant hepatic failure. Lancet 1980; 1: 173 5.
  • 42
    O’Grady JG, Gimson AE, O’Brien CJ, Pucknell A, Hughes RD, Williams R. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988; 94: 1186 92.
  • 43
    Schechter DC, Nealon TF, Gibbon JH. A simple extracorporeal device for reducing elevated blood ammonia levels. Surgery 1958; 44: A892 7(Abstract).
  • 44
    Ching NP, Nealon TF, Gibbon JH. An extracorporeal device for hepatic coma. J Am Med Assoc 1963; 183: A350 4(Abstract).
  • 45
    Juggi JS. Extracorporeal cation exchange circuits in the treatment of hyperammonemia of hepatic failure. Med J Aust 1973; 60: A926 30(Abstract).
  • 46
    Juggi JS. Haemoperfusion through cation exchange columns in the treatment of ammonia intoxication in dogs. Proc Soc Exp Biol Med 1971; 137: 39 42.
  • 47
    Juggi JS. In-vivo studies with a cation exchange resin mixture in the removal of excessive ammonium from the extracorporeal circulation system. Aust N Z J Surg 1971; 41: 194 201.
  • 48
    Bihari D, Hughes RD, Gimson AE, et al. Effects of serial resin hemoperfusion in fulminant hepatic failure. Int J Artif Organs 1983; 6: 299 302.
  • 49
    Nagaki M, Hughes RD, Lau JY, Williams R. Removal of endotoxin and cytokines by adsorbents and the effect of plasma protein binding. Int J Artif Organs 1991; 14: 43 50.
  • 50
    Nagaki M, Hughes RD, Keane HM, Lau JY, Williams R. In vitro plasma perfusion through adsorbents and plasma ultrafiltration to remove endotoxin and cytokines. Circ Shock 1992; 38: 182 8.
  • 51
    Zhu XX, Brown GR, St Pierre LE. Adsorption of bilirubin with polypeptide-coated resins. Biomater Artif Cells Artif Organs 1990; 18: 75 93.
  • 52
    Chandy T & Sharma CP. Preparation and performance of chitosan encapsulated activated charcoal (ACCB) adsorbents for small molecules. J Microencapsul 1993; 10: 475 86.
  • 53
    BerkPD. A computer simulation study relating to the treatment of fulminant hepatic failure by haemoperfusion. Proc Soc Exp Med 1977; 155: 535 539.
  • 54
    Hughes RD & Williams R. Use of sorbent columns and haemofiltration in fulminant hepatic failure. Blood Purif 1993; 11: 163 9.
  • 55
    Ash SR, Blake DE, Carr DJ, Harker KD. Push-pull sorbent based pheresis for treatment of acute hepatic failure: the BioLogic-detoxifier/plasma filter System. ASAIO J 1998; 44: 129 39.
  • 56
    Ash SR, Carr DJ, Blake DE, Rainier JB, Demetriou AA, Rozga J. Effect of sorbent-based dialytic therapy with the BioLogic-DT on an experimental model of hepatic failure. ASAIO J 1993; 39: M675 80.
  • 57
    Ash SR, Blake DE, Carr DJ, Carter C, Howard T, Makowka L. Clinical effects of a sorbent suspension dialysis system in treatment of hepatic coma (the BioLogic-DT). Int J Artif Organs 1992; 15: 151 61.
  • 58
    Ash SR, Blake DE, Carr DJ, Carter C, Howard T, Makowka L. Neurologic improvement of patients with hepatic failure and coma during sorbent suspension dialysis. ASAIO Trans 1991; 37: M332 4.
  • 59
    Hughes RD, Pucknell A, Routley D, Langley PG, Wendon JA, Williams R. Evaluation of the BioLogic-DT sorbent-suspension dialyser in patients with fulminant hepatic failure. Int J Artif Organs 1994; 17: 657 62.
  • 60
    Lepore MJ & Martel AJ. Plasmapheresis with plasma exchange in hepatic coma. Methods and results in five patients with acute fulminant hepatic necrosis. Ann Intern Med 1970; 72: 165 74.
  • 61
    Lepore MJ, Stutman LJ, Bonanno CA, Conklin EF, Robilotti JG, McKenna PJ. Plasmapheresis with plasma exchange in hepatic coma. II. Fulminant viral hepatitis as a systemic disease. Arch Intern Med 1972; 129: 900 7.
  • 62
    Buckner CD, Clift RA, Volwiler W, et al. Plasma exchange in patients with fulminant hepatic failure. Arch Intern Med 1973; 132: 487 92.
  • 63
    Turnberg LA, Mahoney MP, Gleeson MH, Freeman CB, Gowenlock AH. Plasmaphoresis and plasma exchange in the treatment of hyperlipaemia and xanthomatous neuropathy in patients with primary biliary cirrhosis. Gut 1972; 13: 976 81.
  • 64
    Larsen FS, Ejlersen E, Hansen BA, Mogensen T, Tygstrup N, Secher NH. Systemic vascular resistance during high-volume plasmapheresis in patients with fulminant hepatic failure: relationship with oxygen consumption. Eur J Gastroenterol Hepatol 1995; 7: 887 92.
  • 65
    Winikoff S, Glassman MS, Spivak W. Plasmapheresis in a patient with hepatic failure awaiting liver transplantation. J Pediatr 1985; 107: 547 9.
  • 66
    Kondrup J, Almdal T, Vilstrup H, Tygstrup N. High volume plasma exchange in fulminant hepatic failure. Int J Artif Organs 1992; 15: 669 76.
  • 67
    Larsen FS, Hansen BA, Jorgensen LG, Secher NH, Kirkegaard P, Tygstrup N. High-volume plasmapheresis and acute liver transplantation in fulminant hepatic failure. Transplant Proc 1994; 26: 17881788.
  • 68
    Larsen FS, Hansen BA, Ejlersen E, et al. Cerebral blood flow, oxygen metabolism and transcranial Doppler sonography during high-volume plasmapheresis in fulminant hepatic failure. Eur J Gastroenterol Hepatol 1996; 8: 261 5.
  • 69
    Hori M, Austen WG, McDermott WV Jr. Role of hepatic arterial blood flow and hepatic nerves on renal circulation and function. II. Chronic studies in the dog. Ann Surg 1965; 162: 949 58.
  • 70
    Hori M, Neto AC, Austen WG, McDermott WV Jr. Isolated in vivo hepatorenal perfusion in the dog. Circulatory and functional response of the kidney to hepatic anoxia. J Surg Res 1967; 7: 413 17.
  • 71
    Eiseman B, Liem DS, Raffucci F. Heterologous liver perfusion in treatment of hepatic failure. Ann Surg 1965; 162: 329 45.
  • 72
    Abouna GM. Improved technique of exchange transfusion for hepatic coma. Surg Gynecol Obstet 1972; 134: 658 62.
  • 73
    Abouna GM. Extracorporeal liver perfusion for hepatic coma. Lancet 1971; 1: 11851185.
  • 74
    Waldschmidt J, Beck G, Botsch H, et al. [Clinical and experimental experiences with liver perfusion]. Z Exp Chir 1971; 4: 209 15.
  • 75
    Lie TS, Dengler HJ, Gutgemann A, et al. [Extracorporeal perfusion with baboon liver in the treatment of hepatic coma (author’s translation)]. Dtsch Med Wochenschr 1977; 102: 1506 11.
  • 76
    Lie TS, Gutgemann A, Siedeck M, et al. [Treatment of hepatic coma using extracorporeal perfusion with baboon and human liver as well as with activated charcoal]. Langenbecks Arch Chir 1976; Suppl.): 99 103.
  • 77
    Lie TS, Ronschke A, Ukigusa M, Rommelsheim K. [Indication for the treatment of hepatic failure with baboon liver perfusion]. MMW Munch Med Wochenschr 1983; 125: 223 6.
  • 78
    Gundermann KJ & Lie TS. Treatment of acute hepatic failure by hemoperfusion over baboon and human livers: alphafetoprotein levels in serum. Artif Organs 1980; 4: 27 9.
  • 79
    Fox IJ, Langnas AN, Fristoe LW, et al. Successful application of extracorporeal liver perfusion: a technology whose time has come. Am J Gastroenterol 1993; 88: 1876 81.
  • 80
    Byrne GW, McCurry KR, Martin MJ, McClellan SM, Platt JL, Logan JS. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation 1997; 63: 149 55.
  • 81
    Pascher A, Poehlein C, Storck M, et al. Immunopathological observations after xenogeneic liver perfusions using donor pigs transgenic for human decay-accelerating factor. Transplantation 1997; 64: 384 91.
  • 82
    Pascher A, Stangl M, Hammer C. Impact of immunoadsorption on complement activation, immunopathology, and hepatic perfusion during xenogeneic pig liver perfusion. Transplantation 1998; 65: 737 40.
  • 83
    Yun S, Gustafsson K, Fabre JW. Suppression of human anti-porcine T-cell immune responses by major histocompatibility complex class II transactivator constructs lacking the amino terminal domain. Transplantation 1998; 66: 103 11.
  • 84
    Hammer C, Linke R, Wagner F, Diefenbeck M. Organs from animals for man. Int Arch Allergy Immunol 1998; 116: 5 21.
  • 85
    Kimoto S. The artificial liver, experiments and clinical application. Trans Am Soc Artif Intern Organs 1959; 5: 102 12.
  • 86
    Hori M. Will artificial liver therapy ever become reality? Historical aspects and future prospects of the artificial liver. Artif Organs 1988; 12: 293 5.
  • 87
    Mikami J, Moto M, Nishimura A, Sasaki E, Nose Y. Surgical treatment of acute liver failure II: an experimental study of extracorporeal metabolism in the artificial liver using slices of canine liver [Japanese]. Jpn J Gastroenterol 1959; 56: 1022 5.
  • 88
    Nose Y, Mikami J, Kasai Y, Sasaki E, Agishi T, Danjo Y. An experimental artificial liver utilizing extracorporeal metabolism with slices of granulated canine liver. Trans Am Soc Artif Intern Organs 1963; 9: 358 62.
  • 89
    Osanai M, Ogawa K, Lee GH. Phenobarbital causes apoptosis in conditionally immortalized mouse hepatocytes depending on deregulated c-myc expression: characterization of an unexpected effect. Cancer Res 1997; 57: 2896 903.
  • 90
    Elcin YM, Dixit V, Gitnick G. Hepatocyte attachment on biodegradable modified chitosan membranes: In vitro evaluation for the development of liver organoids. Artif Organs 1998; 22: 837 46.
  • 91
    Lora JM, Rowader KE, Soares L, Giancotti F, Zaret KS. Alpha(3)beta(1)-integrin as a critical mediator of the hepatic differentiation response to the extracellular matrix. Hepatology 1998; 28: 1095 104.
  • 92
    Selden C, Roberts E, Stamp G, et al. Comparison of three solid phase supports for promoting three-dimensional growth and function of human liver cell lines. Artificial Organs 1998; 22: 308 19.
  • 93
    Gerlach JC. Development of a hybrid liver support system: a review. Int J Artif Organs 1996; 19: 645 54.
  • 94
    Gerlach JC. Long-term liver cell cultures in bioreactors and possible application for liver support. Cell Biol Toxicol 1997; 13: 349 55.
  • 95
    Gerlach JC, Schnoy N, Vienken J, Smith M, Neuhaus P. Comparison of hollow fibre membranes for hepatocyte immobilisation in bioreactors. Int J Artif Organs 1996; 19: 610 16.
  • 96
    Tarentino AL & Galivan J. Membrane characteristics of adult rat liver parenchymal cells in primary monolayer culture. In Vitro 1980; 16: 833 46.
  • 97
    Gerlach JC, Schnoy N, Encke J, Smith MD, Muller C, Neuhaus P. Improved hepatocyte in vitro maintenance in a culture model with woven multicompartment capillary systems: electron microscopy studies. Hepatology 1995; 22: 546 52.
  • 98
    Gerlach JC, Encke J, Hole O, Muller C, Ryan CJ, Neuhaus P. Bioreactor for a larger scale hepatocyte in vitro perfusion. Transplantation 1994; 58: 984 8.
  • 99
    Sielaff TD, Nyberg SL, Rollins MD, et al. Characterization of the three-compartment gel-entrapment porcine hepatocyte bioartificial liver. Cell Biol Toxicol 1997; 13: 357 64.
  • 100
    Nyberg SL, Shatford RA, Payne WD, Hu WS, Cerra FB. Primary culture of rat hepatocytes entrapped in cylindrical collagen gels: an in vitro system with application to the bioartificial liver. Rat hepatocytes cultured in cylindrical collagen gels. Cytotechnology 1992; 10: 205 15.
  • 101
    Sussman NL, Chong MG, Koussayer T, et al. Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology 1992; 16: 60 5.
  • 102
    Rozga J, Williams F, Ro MS, et al. Development of a bioartificial liver: properties and function of a hollow-fiber module inoculated with liver cells. Hepatology 1993; 17: 258 65.
  • 103
    Rozga J, Holzman MD, Ro MS, et al. Development of a hybrid bioartificial liver. Ann Surg 1993; 217: 502 9.
  • 104
    Gerlach JC. Long-term liver cell cultures in bioreactors and possible application for liver support. Cell Biol Toxicol 1997; 13: 349 55.
  • 105
    Kelly JH, Koussayer T, He D, Chong MG, Sussman NL. Assessment of an extracorporeal assist device in anhepatic dogs. Artificial Organs 1992; 16: 418 22.
  • 106
    Kelly JH, Koussayer T, Chong MG, Sussman NL. An improved model of acetaminophen-induced fulminant hepatic failure in dogs. Hepatology 1992; 15: 329 35.
  • 107
    Wood RP, Katz SM, Ozaki CF, et al. Extracorporeal liver assist device (ELAD): a preliminary report. Transplant Proc 1993; 25: 53 4.
  • 108
    Sussman NL, Gislason GT, Conlin CA, Kelly JH. The Hepatix extracorporeal liver assist device: initial clinical experience. Artif Organs 1994; 18: 390 6.
  • 109
    Kelly JH & Sussman NL. The hepatix extracorporeal liver assist device in the treatment of fulminant hepatic failure. ASAIO J 1994; 40: 83 5.
  • 110
    Ellis AJ, Hughes RD, Wendon JA, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996; 24: 1446 51.
  • 111
    Neuzil DF, Rozga J, Moscioni AD, et al. Use of a novel bioartificial liver in a patient with acute liver insufficiency. Surgery 1993; 113: 340 3.
  • 112
    Demetriou AA, Rozga J, Podesta L, et al. Early clinical experience with a hybrid bioartificial liver. Scand J Gastroenterol Suppl 1995; 208: 111 17.
  • 113
    Chen SC, Hewitt WR, Watanabe FD, et al. Clinical experience with a porcine hepatocyte-based liver support system. Int J Artif Organs 1996; 19: 664 9.
  • 114
    Watanabe FD, Mullon CJP, Hewitt WR, et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg 1997; 225: 484 91.
  • 115
    Rozga J, Podesta L, Lepage E, et al. A bioartificial liver to treat severe acute liver failure. Ann Surg 1994; 219: 538 44.
  • 116
    Naik S, Trenkler D, Santangini H, Pan J, Jauregui HO. Isolation and culture of porcine hepatocytes for artificial liver support. Cell Transplant 1996; 5: 107 15.
  • 117
    Jauregui HO & Gann KL. Mammalian hepatocytes as a foundation for treatment in human liver failure. J Cell Biochem 1991; 45: 359 65.
  • 118
    Martin U, Steinhoff G, Kiessig V, et al. Porcine endogenous retrovirus (PERV) was not transmitted from transplanted porcine endothelial cells to baboons in vivo. Transpl Int 1998; 11: 247 51.
  • 119
    Patience C, Patton GS, Takeuchi Y, et al. No evidence of pig DNA or retroviral infection in patients with short-term extracorporeal connection to pig kidneys [see comments]. Lancet 1998; 352: 699 701.
  • 120
    Heneine W, Tibell A, Switzer WM, et al. No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts [see comments]. Lancet 1998; 352: 695 9.
  • 121
    Sutherland DE, Numata M, Matas AJ, Simmons RL, Najarian JS. Hepatocellular transplantation in acute liver failure. Surgery 1977; 82: 124 32.
  • 122
    Sommer BG, Sutherland DE, Matas AJ, Simmons RL, Najarian JS. Hepatocellular transplantation for treatment of D-galactosamine-induced acute liver failure in rats. Transplant Proc 1979; 11: 578 84.
  • 123
    Eguchi S, Lilja H, Hewitt WR, Middleton Y, Demetriou AA, Rozga J. Loss and recovery of liver regeneration in rats with fulminant hepatic failure. J Surg Res 1997; 72: 112 22.
  • 124
    Arkadopoulos N, Lilja H, Suh KS, Demetriou AA, Rozga J. Intrasplenic transplantation of allogeneic hepatocytes prolongs survival in anhepatic rats. Hepatology 1998; 28: 1365 70.
  • 125
    Sun AM, Cai Z, Shi Z, Ma F, O’Shea GM. Microencapsulated hepatocytes: an in vitro and in vivo study. Biomater Artif Cells Artif Organs 1987; 15: 483 96.
  • 126
    Mito M, Kusano M, Kawaura Y. Hepatocyte transplantation in man. Transplant Proc 1992; 24: 3052 3.
  • 127
    Mito M & Sawa M. Hepatocyte transplantation: past, present and future. Wiad Lek 1997; 50 (Suppl. 1): 416 9.
  • 128
    Habibullah CM, Syed IH, Qamar A, Taher Uz Z. Human fetal hepatocyte transplantation in patients with fulminant hepatic failure. Transplantation 1994; 58: 951 2.
  • 129
    Soriano HE, Wood RP, Kang DC, Ferry GD. Hepatocellular transplantation (HCT) in children with fulminant liver failure (FLF). Hepatology 1997; 26: A239A239(Abstract).
  • 130
    Bilir BM, Guenette D, Ostrowska A, Durham J. Percutaneous hepatocyte transplantation (PHT) in liver failure. Hepatology 1997; 26: A252A252(Abstract).
  • 131
    Strom SC, Fisher RA, Thompson MT, et al. Hepatocyte transplantation as a bridge to orthotopic liver transplantation in terminal liver failure. Transplantation 1997; 63: 559 69.
  • 132
    Bernal W, Donaldson P, Underhill J, Wendon J, Williams R. Tumor necrosis factor genomic polymorphism and outcome of acetaminophen (paracetamol)-induced acute liver failure. J Hepatol 1998; 29: 53 9.